Primary Record
Melanotan II
- In stock
- 2,973 g
- Purity
- 98.3 %
- CAS
- 121062-08-6
Compound Identifiers & Properties
- CAS
- 121062-08-6
- PubChem CID
- 92432
- SMILES
- CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N)NC(=O)C
- Canonical SMILES
- CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O
Names & Synonyms
- Melanotan II
- Melanotan-II
- MT-II
- Melanotan (MT)-II
- 121062-08-6
- Melatonan
- MelanotanII
- Tanshinone VI
- Melanotan -Ii
- Melanotan II?
- Melanotan II acetate
- MTII
- Asp5
- MTII Melanotan-II
- Melanotan II acetate salt
- D-Phe7
- Melanotan II Acetate
- UPF5CJ93X7
- RefChem:925444
- Melanotan II(MT-II)/
- D07ISM
- D0KF9K
- D0YB7F
- Melanotan I(SCENESSE)/
- UNII-UPF5CJ93X7
- 1024.18(freebasebasis)
- CHEMBL430239
- C50H69N15O9
- DTXSID90153135
- MELANOTAN II [WHO-DD]
- AC1L3O47
- ebi_340792
- GTPL1323
- orb1296657
- SCHEMBL1047531
- DTXCID3075626
- SCHEMBL29473785
- CHEBI:195326
- CID92432
- EX-A7394
- HY-P0267
- 121062-08-6 (non-salt)
- ABP000198
- ABP000529
- BDBM50027084
- BDBM50184359
- CM-505
- MFCD01318793
- MFCD06795842
- AKOS015994654
- C50H69N15O9??xC2HF3O2
- ACN-049462
- BAT-006134
- C50-H69-N15-O9
- CS-7016
- HS-2017
- Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2
- Melanotan II, MTII, Bremelanotide amide
- NCGC00167281-01
- DA-55328
- FA109114
- I026
- LS-172479
- Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
- B7110
- A12646
- F93947
- Ac-Nle-Cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
- 062M086
- A804647
- Q423855
- (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide
- (3S,6S,9R,12S,15S,23S)-12-((1H-imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide
- L-Lysinamide, N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-7)-peptide
- Acetyl-(Nle4,Asp5,D-Phe7,Lys10)-cyclo-alpha-MSH (4-10) amide
- (3S,6S,9R,12S,15S,23S)-12-((1H-imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-((diaminomethylene)amino)propyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide
- (3S,6S,9R,12S,15S,23S)-15-((S)-2-acetylamino-hexanoylamino)-9-benzyl-6-(3-guanidino-propyl)-12-(3H-imidazol-4-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18hexaaza-cyclotricosane-23-carboxylic acid amide
- (3S,6S,9R,12S,15S,23S)-15-[(N-Acetyl-L-norleucyl)amino]-9-benzyl-6-{3-[(diaminomethylidene)amino]propyl}-12-[(1H-imidazol-5-yl)methyl]-3-[(1H-indol-3-yl)methyl]-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide
- (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-(3-guanidinopropyl)-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide
- (3S,6S,9R,12S,15S,23S)-9-BENZYL-6-(3-CARBAMIMIDAMIDOPROPYL)-15-[(2S)-2-ACETAMIDOHEXANAMIDO]-12-(1H-IMIDAZOL-4-YLMETHYL)-3-(1H-INDOL-3-YLMETHYL)-2,5,8,11,14,17-HEXAOXO-1,4,7,10,13,18-HEXAAZACYCLOTRICOSANE-23-CARBOXAMIDE
- (3S,6S,9R,12S,15S,23S)-9-benzyl-6-{3-[(diaminomethylidene)amino]propyl}-15-[(2S)-2-acetamidohexanamido]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide
- *Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2*Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2*Ac-cyclo[Nle4
- 75921-69-6
- L-LYSINAMIDE, N-ACETYL-L-NORLEUCYL-L-.ALPHA.-ASPARTYL-L-HISTIDYL-D-PHENYLALANYL-L-ARGINYL-L-TRYPTOPHYL-, CYCLIC (2->7)-PEPTIDE
- Lys10]|A-MSH4 C10-NH2*N-Acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl- D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysinamide (2->7)-lactam*PT-14